Livzon Pharmaceutical Group Inc.
LVZPF
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.63B
Close$
$14.00
168.2% upside
Current Fair Value
168.2% upsideUndervalued by 168.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.63 Billion |
|---|---|
| Enterprise Value | $1.51 Billion |
| Dividend Yield | $0.21 (4.69%) |
| Earnings per Share | $2.24 |
| Beta | 0.24 |
| Outstanding Shares | 887,907,171 |
Return
| Return on Equity | 12.44% |
|---|---|
| Return on Assets | 7.05% |
| Return on Invested Capital | 14.56% |
Valuation & Multiples
| P/E Ratio | 16.14 |
|---|---|
| PEG | -35.79 |
| Price to Sales | 0.44 |
| Price to Book Ratio | 0.33 |
| Enterprise Value to Revenue | 0.14 |
| Enterprise Value to EBIT | 0.68 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 2.86 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$434.66 M
Average shareholder expectationNext Earnings Call
Expected Date
October 23, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$381.84 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Livzon Pharmaceutical Group Inc.
8,878 employees
CEO: Daping Liu Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturin...